One-Year Outcomes of Preserflo™ MicroShunt Implantation versus Trabeculectomy for Pseudoexfoliation Glaucoma

This retrospective, single-center study evaluates the safety and efficacy of Preserflo (TM) MicroShunt (MicroShunt) implantations compared to trabeculectomies (TETs) in patients diagnosed with pseudoexfoliation glaucoma (PEXG). A total of 31 eyes from 28 patients received a MicroShunt implantation, and 29 eyes from 26 patients received a TET. Surgical success was defined as an intraocular pressure (IOP) between 5 mmHg and 17 mmHg at the end of the follow-up period, no need for surgical revisions or secondary glaucoma surgery, and no loss of light perception. In the MicroShunt group, the mean IOP dropped from 20.8 +/- 5.9 mmHg at baseline to 12.4 +/- 2.8 mmHg (p < 0.0001) after one year. In the TET group, the mean IOP dropped from 22.3 +/- 6.5 mmHg to 11.1 +/- 3.7 mmHg (p < 0.0001) after 12 months. In both of the groups, the mean number of medications was reduced significantly (MicroShunt from 2.7 +/- 1.2 to 0.2 +/- 0.7; p < 0.0001 vs. TET from 2.9 +/- 1.2 to 0.3 +/- 0.9; p < 0.0001). Considering the success rates, 83.9% of the MicroShunt eyes achieved complete success, and 90.3% qualified for success at the end of the follow-up period. In the TET group, the rates were 82.8% and 93.1%, respectively. The postoperative complications were comparable between both groups. In conclusion, the MicroShunt implantation demonstrated non-inferiority regarding its efficacy and safety profile compared to TET in PEXG at a follow-up of one year.

Automated summary

This retrospective single-center study compared the safety and effectiveness of Preserflo (TM) MicroShunt (MicroShunt) implantations with trabeculectomies (TETs) in patients with pseudoexfoliation glaucoma (PEXG). The results showed that both treatments significantly reduced intraocular pressure (IOP) and the need for medications. The success rates and postoperative complications were comparable between the two groups. The study concluded that MicroShunt implantation is non-inferior to TET in terms of efficacy and safety in PEXG patients.